| Literature DB >> 29884186 |
Diana Luz Juárez-Flores1,2, Ingrid González-Casacuberta1,2, Mario Ezquerra3,4, María Bañó1,2, Francesc Carmona-Pontaque5, Marc Catalán-García1,2, Mariona Guitart-Mampel1,2, Juan José Rivero1,2, Ester Tobias1,2, Jose Cesar Milisenda1,2, Eduard Tolosa3,4, Maria Jose Marti3,4, Ruben Fernández-Santiago3,4, Francesc Cardellach1,2, Constanza Morén6,7, Glòria Garrabou8,9.
Abstract
BACKGROUND: Mutations in leucine rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson's disease (PD). Mitochondrial and autophagic dysfunction has been described as etiologic factors in different experimental models of PD. We aimed to study the role of mitochondria and autophagy in LRRK2 G2019S -mutation, and its relationship with the presence of PD-symptoms.Entities:
Keywords: Autophagy; Fibroblasts; G2019S; Galactose; Glucose; LRRK2; Mitochondrial dynamics; Mitochondrial dysfunction; Non-manifesting carriers; Parkinson’s disease
Mesh:
Substances:
Year: 2018 PMID: 29884186 PMCID: PMC5994110 DOI: 10.1186/s12967-018-1526-3
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Epidemiological characteristics of the cohorts
| Group | N | Gender | Age (years) | |||
|---|---|---|---|---|---|---|
| Male | Female | Range | Mean | SEM | ||
| NM- | 6 | 3 (50%) | 3 (50%) | 34–61 | 46.67 | 4.04 |
| PD- | 7 | 3 (42.85%) | 4 (57.15%) | 44–71 | 60.57 | 3.15 |
| Control | 8 | 3 (37.50%) | 5 (62.50%) | 41–69 | 56.00 | 3.63 |
Epidemiological data of the studied cohorts at the time of skin biopsy. No significant differences were found in age or gender between groups
NM-LRRK2: Non-manifesting LRRK2-mutation carriers; PD-LRRK2: patients with LRRK2-mutation and clinically manifest PD; N: Number of cases enrolled; SEM: Standard error of the mean
Fig. 1Mitochondrial phenotype of LRRK2-mutation carriers. Mitochondrial parameters measured in LRRK2-mutation carriers, without clinical symptoms of PD (NM-LRRK2) or with clinically manifest PD (PD-LRRK2) represented as a percentage of decrease/increase when compared to healthy controls, arbitrarily assigned as 0% (black, dotted line) in glucose (blue line) and galactose media (red line). The letters (a), (a’), (b) and (b’), indicate those cases in which a statistical difference within the two analysed groups and controls was found: (a) p < 0.05 when comparing NM-LRRK2 to controls in glucose media, (a’) p < 0.05 when comparing NM-LRRK2 to controls in galactose media, (b) p < 0.05 when comparing PD-LRRK2 to controls in glucose media and (b’) p < 0.05 when comparing PD-LRRK2 to controls in galactose media. In summary, fibroblasts of NM-LRRK2 showed a pattern similar to controls in glucose, except for early disruption of MMP. When subjected to mitochondrial challenging conditions, global mitochondrial function and dynamics trended to ameliorate, towards ATP production (A). Fibroblasts of PD-LRRK2 in glucose trended towards a deranged mitochondrial function when compared to controls. When subjected to galactose media, PD-LRRK2 fibroblasts presented an inefficient increase of mitochondrial function and worsened mitochondrial dynamics, leading to increased oxidative stress (B)
Fig. 2Mitochondrial function. Results are represented by mean ± SEM, comparing controls (n = 8; white bars), NM-LRRK2-mutation, (n = 6; grey bars) and PD-LRRK2 (n = 7; black bars) in glucose and galactose media. a Citrate synthase levels remained constant between groups in both media. b A trend to decrease CI enzymatic activity in NM-LRRK2 and PD-LRRK2 was observed in glucose media, and PD-LRRK2 patients harbouring the mutation increased their activity with respect to controls in galactose media (p = 0.04). c Oxygen consumption trended to reproduce the pattern of CI enzymatic activity. After exposure to galactose media, a non-significant increment in O2 consumption was observed in fibroblasts of NM-LRRK2 subjects with respect to controls (p = 0.35). d Complex IV enzymatic function remained similar in all groups, showing a trend to increase in NM-LRRK2 subjects with respect to controls in glucose and galactose media (p = 0.14 in both cases). e ATP levels tended to decrease in both groups in glucose media (p = 0.18 when comparing PD-LRRK2 with controls). f Number of depolarized mitochondria was increased in NM-LRRK2 when compared to controls in glucose media (p = 0.04), with the same trend observed for PD-LRRK2 although without reaching statistical significance (p = 0.14). g Oxidative damage trended to increase in PD-LRRK2 patients in both conditions when comparing them to controls. h Apoptotic rate tended to decrease in the NM-LRRK2 group in both media
Fig. 3Mitochondrial dynamics. a Representative images of mitochondrial network obtained by confocal microscopy. NM-LRRK2: Non-manifesting carriers of LRRK2-mutation; PD-LRRK2: patients with LRRK2-mutation and clinically manifest PD. b–e. Results are represented by mean ± SEM, comparing controls (n = 8; white bars), NM-LRRK2 (n = 5, gray bars) and PD-LRRK2 (n = 7; black bars) in glucose and galactose media. Briefly, in fibroblasts of NM-LRRK2 a significant increase in mitochondrial network in standard conditions (glucose) was observed when compared to controls (b). When NM-LRRK2 fibroblasts were subjected to mitochondrial challenging conditions (galactose), an improvement of mitochondrial dynamics was seen, by decreased circularity (c) and trends to increase form factor (e), accounting for longer, more branched mitochondria. Fibroblasts of PD-LRRK2 showed a pattern similar to controls in standard (glucose) conditions and a handicapped response when exposed to mitochondrial challenging conditions (galactose) as shown by decreased aspect ratio (d), accounting for shorter mitochondria
Fig. 4Autophagy. a Representative images (original images have been cropped and are available at request) of autophagy markers measured by Western blot comparing: NM-LRRK2: Non-manifesting carriers of LRRK2-mutation; PD-LRRK2: patients with LRRK2-mutation and clinically manifest PD. (SQSTM1/p62)/β-actin: Autophagy substrate, LC3B-I/β-actin: autophagy receptor, basal form. LC3B-II/β-actin: autophagy receptor, lipidated form. b Representative images of autophagosome formation (UT) and accumulation after 8 h of treatment with 100 nM bafilomycin (BAF) obtained by confocal microscopy. c, d Results are represented by mean ± SEM, comparing controls (n = 8; white bars), NM-LRRK2-mutation (n = 6, gray bars) and PD-LRRK2 (n = 7; black bars) in either glucose or galactose media and at basal state, and after 4 and 8 h treatment with bafilomycin (0, 4, 8). Autophagy initiation was upregulated in NM-LRRK2 subjects in glucose and galactose media when compared to controls (+ 118.4% SQSTM1/P62, p = 0.014 and + 114.44% SQSTM1/P62, p = 0.009, respectively) and trends to increase autophagy substrate were observed in PD-LRRK2 in both media (c). Autophagosome formation trended to increase at 4 and 8 h of bafilomycin treatment in NM-LRRK2 and was significantly decreased in PD-LRRK2 when compared to NM-LRRK2 subjects in glucose media at 4 and 8 h of bafilomycin treatment (− 79 to 86%, p = 0.042 and − 71.26%, p = 0.22 respectively) (d)